James Gordon Liddy
Director · Hepion Pharmaceuticals, Inc.
- 2025
- Aug 21, 2026
- 2
Summary
Latest filing:
James Gordon Liddy is Director of Hepion Pharmaceuticals, Inc. (HEPA). 2 SEC Form 4 filings on record going back to 2025, most recently on 21 August 2026.
Trading pattern
InsiderAlpha's records for James Gordon Liddy go back to 2025: 2 primary Form 4 filings, an average of 1.0 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies James Gordon Liddy files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Vincent S. Lopriore - $750K in HEPA purchases and sales in the last 12 months
- Michael J. Purcell - $150K in HEPA purchases and sales in the last 12 months
- Sireesh Appajosyula - $150K in HEPA purchases and sales in the last 12 months
- Gary S. Stetz - $150K in HEPA purchases and sales in the last 12 months
- Gary S. Stetz II - $25K in HEPA purchases and sales in the last 12 months
- Danina Fisher - $10K in HEPA purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is James Gordon Liddy?
James Gordon Liddy is a corporate insider, tracked as Director of Hepion Pharmaceuticals, Inc. (HEPA). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has James Gordon Liddy submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.